株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

神経変性疾患の新興治療法パートII:ハンチントン病、筋萎縮性側索硬化症(HD・ALS)

Emerging Therapeutics for Neurodegenerative Diseases Part II: Huntington's Disease and Amyotrophic Lateral Sclerosis (HD & ALS)

発行 Frost & Sullivan 商品コード 913123
出版日 ページ情報 英文 71 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
神経変性疾患の新興治療法パートII:ハンチントン病、筋萎縮性側索硬化症(HD・ALS) Emerging Therapeutics for Neurodegenerative Diseases Part II: Huntington's Disease and Amyotrophic Lateral Sclerosis (HD & ALS)
出版日: 2019年09月17日 ページ情報: 英文 71 Pages
概要

現在、神経変性疾患は先進国における主な死因の第1位となっています。わずかな治療法しかなく成功率もかなり低くなっています。臨床、科学の双方の分野で、神経変性疾患の治療と診断のための新たな治療法を開発しようと取り組んでいます。

当レポートでは、世界の神経変性疾患の新興治療法市場について調査し、技術的動向とステークホルダーの動向、地域別法規制環境などについてまとめています。

第1章 エグゼクティブサマリー

第2章 技術環境と動向

  • 神経変性疾患:事実の課題
  • 神経変性疾患:多因子的発症
  • 神経変性疾患:誘引因子
  • 神経変性疾患:新興のアプローチ
  • 神経変性疾患:革新的薬剤

第3章 神経変性疾患に対処するための新興の治療法

  • ALSの現在の治療法
  • ALSの有望な治療法
  • ALSの追加的治療法
  • ALSの新規治療法
  • ALSの主要な治療法
  • ALSの早期の治療法
  • ALSの治療候補
  • HDの現在の治療法
  • HDの有望な治療法

第4章 技術動向レビューと評価

第5章 技術レーダーとインテリジェントソリューション

  • ハンチントン病:革新的アプローチ
  • 筋萎縮性側索硬化症:大手企業

第6章 市場潜在性と技術導入

  • 神経変性疾患市場の可能性
  • 環境影響因子
  • 最良の業界パートナーシップ:SWOT分析
  • 神経変性疾患のための連携的枠組み
  • パートナービジネスと技術能力
  • 連携の取り組みを通じた目的のための重要側面

第7章 ビジネス環境と知的財産分析

第8章 業界連絡先

第9章 付録

目次
Product Code: D8EE

Novel Targeted Therapeutic Strategies Technologies Around Neurodegenerative Disorders - From Palliative to Future Interventions

At present, only a few therapies are available with relatively low success. Both, the clinical and the scientific communities are critically devoted to develop new therapeutic approaches to treat and diagnose neurodegenerative diseases.

At present days, neurodegenerative diseases represent one of the main causes of death in the industrialized economy. Overall characterized by a loss of neurons in particular regions of the nervous system, the subsequent decline in cognitive and motor function that patients experience in these diseases is associated with nerve cell loss.

The most common denominator among neurodegenerative diseases, in addition to nerve cell loss is inflammation. Although, a series of mutant genes and environmental toxins are related to neurodegenerative disorders, the causal mechanisms remain poorly understood.

Neurodegenerative diseases can be defined as multifactorial debilitating disorders of the nervous system. Overall, neurodegenerative diseases affect approximately 30 million individuals worldwide, according to the World Health Organization (WHO).

Factors Contributing to Neurodegenerative Diseases

The factors contributing to the onset of neurodegenerative diseases are multiple. Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) diseases are well-established as the consequence of misfolding and dysfunctional trafficking of proteins. However, other factors including mitochondrial dysfunction, oxidative stress, aging, and environmental issues are deeply associated with the onset of neurodegeneration.

Molecular Mechanisms Underlying Neurodegeneration

Although all these factors have been demonstrated to significantly contribute to the etiology of common neurodegenerative diseases, some molecular mechanisms underlying neurodegeneration remain unveiled.

Present efforts are focused on the identification of viable drug targets and biomarkers for early diagnosis of the diseases, in order to develop the best suited therapies.

Some Multifactorial Conditions to Watch:

  • Abnormal protein dynamics
  • Defective protein degradation and aggregation
  • Oxidative stress
  • Free radical formation
  • Impaired bioenergetics
  • Mitochondrial dysfunction
  • Exposure to toxic metals and pesticides
  • Others

Coverage of Neurodegenerative Diseases Technologies:

This research service, ‘Emerging Therapeutics for Neurodegenerative Diseases', focuses on the leading technology and business trends that are making possible the implementation of cutting-edge innovations that help to face the present and future challenges of the neurodegenerative disease therapeutics sector.

The tendencies depicted in this study will help to drive the sustainability of the neurodegenerative disease therapeutics industry by directly exhibiting the principal challenges faced by leading biopharmaceutical and biotechnology companies to develop new product modalities in an affordable and high performance style, while getting market acceptance and achieving market leadership by translating technology innovation to market competitiveness

The study covers the following topics:

  • Technology roadmap, trends, capabilities, and applications targeted
  • Stakeholder activities, influence, industry initiatives, investment environment, and funding support
  • Regional and global regulation landscape and standardization approaches for tackling challenges
  • Technology benchmarking for smart decisions

An appendix is included, comprising lists of major industry influencers found in the field.

Table of Contents

1.0 Executive Summary

  • 1.1 Facts and Findings: Neurodegenerative Diseases
  • 1.2 Research Focus: Neurodegenerative Diseases
  • 1.3 Research Scope: Foreseeing Challenges and Solutions
  • 1.4 Analysis Framework: Frost & Sullivan's Core Value
  • 1.5 Research Methodology

2.0 Technology Landscape and Trends

  • 2.1 Neurodegenerative Diseases: Facts and Challenges
  • 2.2 Neurodegenerative Diseases: Multifactorial Onsets
  • 2.3 Neurodegenerative Diseases: Concurrent Triggering Factors
  • 2.4 Neurodegenerative Diseases: Emerging Approaches
  • 2.5 Neurodegenerative Diseases: Innovative Agents

3.0 Emerging Therapies to Address Neurodegeneration

  • 3.1 Present Therapies for ALS
  • 3.2 Promising Therapies for ALS
  • 3.3 Additional Therapies for ALS
  • 3.4 Novel Therapies for ALS
  • 3.5 Major Therapies for ALS
  • 3.6 Early Stage Therapies for ALS
  • 3.7 Candidate Therapies for ALS
  • 3.8 Present Therapies for HD
  • 3.9 Promising Therapies for HD

4.0 Technology Status Review and Assessment

  • 4.1 Neurodegenerative Preclinical Models: Needs and Complexities
  • 4.2 Neurodegenerative Models' Pitfalls : Huntington's Disease
  • 4.3 Neurodegenerative Models' Pitfalls : Amyotrophic Lateral Sclerosis
  • 4.4 Present Status of Therapeutics Technology
  • 4.5 Huntington's Disease Drug Development Status
  • 4.6 Amyotrophic Lateral Sclerosis Drug Development Status
  • 4.6 Amyotrophic Lateral Sclerosis Drug Development Status (continued)
  • 4.6 Amyotrophic Lateral Sclerosis Drug Development Status (continued)
  • 4.6 Amyotrophic Lateral Sclerosis Drug Development Status (continued)

5.0 Technology Radar and Intelligent Solutions

  • 5.1 Huntington's Disease - Top Innovative Approaches
  • 5.2 Amyotrophic Lateral Sclerosis - Major Firms

6.0 Market Potential and Technology Adoption

  • 6.1 Neurodegenerative Diseases Market Potential
  • 6.2 Overall Environmental Impact Factors
  • 6.3 Best-fit Industry Partnerships: SWOT Analysis
  • 6.4 Collaborative Framework for Neurodegenerative Diseases
  • 6.5 Partners Business and Technology Capabilities
  • 6.6 Key Aspects to Target through Collaborative Initiatives

7.0 Business Landscape and Intellectual Property Analysis

  • 7.1 Actionable Impact on Business Development
  • 7.2 Repercussions in Business and Processes
  • 7.3 Technology Transfer Assessment

8.0 Key Industry Contacts

  • 8.1 Key Industry Influencers
  • 8.1 Key Industry Influencers (continued)
  • 8.1 Key Industry Influencers (continued)
  • 8.1 Key Industry Influencers (continued)
  • 8.1 Key Industry Influencers (continued)

9.0 Appendix

  • 9.1 Huntington's Disease Drug Pipeline
  • 9.1 Huntington's Disease Drug Pipeline (continued)
  • 9.1 Huntington's Disease Drug Pipeline (continued)
  • 9.2 Amyotrophic Lateral Sclerosis's Drug Pipeline
  • 9.2 Amyotrophic Lateral Sclerosis's Drug Pipeline (continued)
  • 9.2 Amyotrophic Lateral Sclerosis's Drug Pipeline (continued)
  • 9.2 Amyotrophic Lateral Sclerosis's Drug Pipeline (continued)
  • 9.2 Amyotrophic Lateral Sclerosis's Drug Pipeline (continued)
  • 9.2 Amyotrophic Lateral Sclerosis's Drug Pipeline (continued)
  • 9.2 Amyotrophic Lateral Sclerosis's Drug Pipeline (continued)
  • 9.2 Amyotrophic Lateral Sclerosis's Drug Pipeline (continued)
  • 9.2 Amyotrophic Lateral Sclerosis's Drug Pipeline (continued)
  • 9.2 Amyotrophic Lateral Sclerosis's Drug Pipeline (continued)
  • Legal Disclaimer
Back to Top